Statistical aspects of bioavailability

Simple item page
dc.contributor.advisorJuritz, June Men_ZA
dc.contributor.authorFresen, John Lawrenceen_ZA
dc.date.accessioned2016-02-15T07:07:42Z
dc.date.available2016-02-15T07:07:42Z
dc.date.issued1985en_ZA
dc.descriptionIncludes bibliography.en_ZA
dc.description.abstractIn 1984 it became legal for pharmacists to offer customers a cheaper generic alternative for a given prescription. The motivation for this was the excessively high cost of brand name drugs. The substitution of a generic alternative for a brand name drug is based on the assumption that drugs with a comparable chemical composition will have a similar therapeutic effect. The fact that this supposition is not always true has been demonstrated by a number of particular drugs, digoxon being perhaps the most vivid example. The objective of this thesis is to review the statistical aspects associated with (i) measuring the bioavailability of a drug (Chapter 2) (ii) establishing the equivalence of a new and standard formulation of a drug (Chapter 3). In the process of reviewing the literature two problems were identified. Firstly, it is commonly assumed that bioavailability parameters follow either the normal or lognormal distribution. This assumption is difficult to defend, hence procedures based on such assumptions became suspect. Secondly, bioavailability is inherently multivariate whereas in practice univariate procedures are employed. Efren's bootstrap method, which does not rest on assumptions about the underlying distribution, is proposed as a tool for assessing bioequivalence. A new measure of bioequivalence, the Index of Concordance, is proposed. This index can be computed with equal ease for univariate or multivariate data using the bootstrap (Chapter 5). The bootstrap idea of resampling the data can also be applied to compartmental modelling of bioavailability data. One result of this is a nonparametric estimate of the underlying distribution of the bioavailability parameters (Chapter 6). The bootstrap is, on its own, a fascinating concept. A review of the bootstrap is given in Chapter 4.en_ZA
dc.identifier.apacitationFresen, J. L. (1985). <i>Statistical aspects of bioavailability</i>. (Thesis). University of Cape Town ,Faculty of Science ,Department of Statistical Sciences. Retrieved from http://hdl.handle.net/11427/17004en_ZA
dc.identifier.chicagocitationFresen, John Lawrence. <i>"Statistical aspects of bioavailability."</i> Thesis., University of Cape Town ,Faculty of Science ,Department of Statistical Sciences, 1985. http://hdl.handle.net/11427/17004en_ZA
dc.identifier.citationFresen, J. 1985. Statistical aspects of bioavailability. University of Cape Town.en_ZA
dc.identifier.ris TY - Thesis / Dissertation AU - Fresen, John Lawrence AB - In 1984 it became legal for pharmacists to offer customers a cheaper generic alternative for a given prescription. The motivation for this was the excessively high cost of brand name drugs. The substitution of a generic alternative for a brand name drug is based on the assumption that drugs with a comparable chemical composition will have a similar therapeutic effect. The fact that this supposition is not always true has been demonstrated by a number of particular drugs, digoxon being perhaps the most vivid example. The objective of this thesis is to review the statistical aspects associated with (i) measuring the bioavailability of a drug (Chapter 2) (ii) establishing the equivalence of a new and standard formulation of a drug (Chapter 3). In the process of reviewing the literature two problems were identified. Firstly, it is commonly assumed that bioavailability parameters follow either the normal or lognormal distribution. This assumption is difficult to defend, hence procedures based on such assumptions became suspect. Secondly, bioavailability is inherently multivariate whereas in practice univariate procedures are employed. Efren's bootstrap method, which does not rest on assumptions about the underlying distribution, is proposed as a tool for assessing bioequivalence. A new measure of bioequivalence, the Index of Concordance, is proposed. This index can be computed with equal ease for univariate or multivariate data using the bootstrap (Chapter 5). The bootstrap idea of resampling the data can also be applied to compartmental modelling of bioavailability data. One result of this is a nonparametric estimate of the underlying distribution of the bioavailability parameters (Chapter 6). The bootstrap is, on its own, a fascinating concept. A review of the bootstrap is given in Chapter 4. DA - 1985 DB - OpenUCT DP - University of Cape Town LK - https://open.uct.ac.za PB - University of Cape Town PY - 1985 T1 - Statistical aspects of bioavailability TI - Statistical aspects of bioavailability UR - http://hdl.handle.net/11427/17004 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/17004
dc.identifier.vancouvercitationFresen JL. Statistical aspects of bioavailability. [Thesis]. University of Cape Town ,Faculty of Science ,Department of Statistical Sciences, 1985 [cited yyyy month dd]. Available from: http://hdl.handle.net/11427/17004en_ZA
dc.language.isoengen_ZA
dc.publisher.departmentDepartment of Statistical Sciencesen_ZA
dc.publisher.facultyFaculty of Scienceen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.subject.otherMathematical Statisticsen_ZA
dc.titleStatistical aspects of bioavailabilityen_ZA
dc.typeMaster Thesis
dc.type.qualificationlevelMasters
dc.type.qualificationnameMScen_ZA
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceThesisen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
thesis_sci_1985_fresen_john_lawrence.pdf
Size:
2.13 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Masters